Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 75mg - darunavir 75mg - hiv protease inhibitors

Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 150mg - darunavir 150mg - hiv protease inhibitors

Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 300mg - darunavir 300mg - hiv protease inhibitors

Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 400mg - darunavir 400mg - hiv protease inhibitors

Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 600mg - darunavir 600mg - hiv protease inhibitors

Kanada - englanti - Health Canada

mylan pharmaceuticals ulc - darunavir - tablet - 800mg - darunavir 800mg - hiv protease inhibitors

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - darunavir - film coated tablet - 400 milligram - protease inhibitors

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - darunavir, quantity: 800 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - adult patients:,darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients:,darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - darunavir, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; crospovidone; colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - adult patients:,darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients:,darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)